Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment DOI Creative Commons
Matteo Augello, Isabell Wagenhäuser, Manuel Krone

и другие.

Vaccine, Год журнала: 2024, Номер 42(25), С. 126184 - 126184

Опубликована: Авг. 3, 2024

Язык: Английский

SARS-CoV-2 neutralizing antibody determination after vaccination using spectrophotometric measurement of lateral flow immunochromatography DOI Creative Commons
Jianglei Ma,

Scott Kaniper,

Yuliya Vabishchevich

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Фев. 24, 2025

Neutralizing antibody titers have been found to be strongly correlated with observed vaccine effectiveness against symptomatic and severe COVID-19. Few non-high complexity assays are currently available detect the presence of neutralizing antibodies. This retrospective single-center cross-sectional study compared performance a lateral flow immunochromatography assay coupled spectrophotometric measurement system for detecting SARS-CoV-2 antibodies an enzyme-linked immunosorbent (ELISA) neutralization in context post-vaccination responses. The limit detection was similar ELISA strong linearity throughout measuring interval. Repeatability, interfering substances, cross-reactivity studies were robust. Results 274 plasma samples on whom RNA test vaccination status, including number manufacturer, known showed positive predictive value (PPV) 99.0% (CI 96.4–99.7%) negative (NPV) 91.9% 83.4–96.2%) ELISA. PPV all manufacturer subgroups > 95% except those individuals who had only 1 Pfizer (PPV 80%). NPV PCR no vaccinations 100% while 88.1% without previous or vaccination. 80% contrast Moderna vaccinations. Alternative methodologies requiring less sophisticated laboratory support measure may useful

Язык: Английский

Процитировано

0

Multiplex ACE2-RBD binding inhibition assay: An integrated tool for assessing neutralizing antibodies to SARS-CoV-2 variants and protection against breakthrough infections DOI
Emma Bloch, Laura García,

Françoise Donnadieu

и другие.

Journal of Immunological Methods, Год журнала: 2025, Номер 541, С. 113886 - 113886

Опубликована: Май 28, 2025

Язык: Английский

Процитировано

0

Viral Dynamic Models During COVID‐19: Are We Ready for the Next Pandemic? DOI Creative Commons
Aurélien Marc, Joshua T. Schiffer, France Mentré

и другие.

CPT Pharmacometrics & Systems Pharmacology, Год журнала: 2025, Номер unknown

Опубликована: Июнь 2, 2025

ABSTRACT Mathematical models have been used for about 30 years to improve our understanding of virus‐host interaction, in particular during chronic infections. During the COVID‐19 pandemic, these provide insights into natural history acute SARS‐CoV‐2 infection, optimize antiviral treatment strategies, understand factors associated with transmission, and surveillance systems. The impact modeling has accelerated by availability unprecedented multidimensional immune data from animal human systems, which enhanced partnerships between experimentalists theorists led exciting new statistical developments. In this mini review, we examine lessons learned pandemic discuss main provided mathematical viral dynamics at different stages outbreak. Although focus on respiratory also consider areas development anticipation future infections or reemerging pathogens.

Язык: Английский

Процитировано

0

A novel quantitative double antigen sandwich ELISA for detecting total antibodies against Candida albicans enolase 1 DOI
Lihui Wang,

Zongzhong He,

Yiyang Guo

и другие.

European Journal of Clinical Microbiology & Infectious Diseases, Год журнала: 2024, Номер 43(9), С. 1815 - 1823

Опубликована: Июль 16, 2024

Язык: Английский

Процитировано

2

Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment DOI Creative Commons
Matteo Augello, Isabell Wagenhäuser, Manuel Krone

и другие.

Vaccine, Год журнала: 2024, Номер 42(25), С. 126184 - 126184

Опубликована: Авг. 3, 2024

Язык: Английский

Процитировано

1